The Short- and Long-Term Efficacy of Non-Invasive Brain Stimulation for Migraine: A Meta-Analysis.

IF 2.5 3区医学 Q2 CLINICAL NEUROLOGY

Journal of Pain Research Pub Date : 2025-09-19 eCollection Date: 2025-01-01 DOI:10.2147/JPR.S529622

Mengya Liu, Yongxia Yong, Hui Zou, Luping Yang, Jinghua Qian

{"title":"The Short- and Long-Term Efficacy of Non-Invasive Brain Stimulation for Migraine: A Meta-Analysis.","authors":"Mengya Liu, Yongxia Yong, Hui Zou, Luping Yang, Jinghua Qian","doi":"10.2147/JPR.S529622","DOIUrl":null,"url":null,"abstract":"Purpose: Non-invasive brain stimulation (NIBS) has shown promising potential in the treatment of migraine; however, its short- and long-term efficacy remains uncertain. This meta-analysis evaluated the effects of NIBS on multiple migraine-related clinical outcomes in both short- and long-term follow-ups.Methods: This PRISMA-compliant review (PROSPERO: CRD42024529488) included RCTs on NIBS for migraine. A comprehensive search was conducted in PubMed, Scopus, The Cochrane, EMBASE, Web of Science, CNKI, and VIP up to April 11, 2024. Outcomes consisted of headache frequency, pain intensity, duration, analgesic intake, and adverse effects. Analyses used RevMan 5.3 and STATA 17.0.Results: Thirteen studies (596 participants) were included. In terms of short-term outcomes, NIBS significantly reduced headache frequency (SMD = -1.47, 95% CI: -2.13 to -0.82) and pain intensity (SMD = -2.09, 95% CI: -3.36 to -0.83). During long-term follow-up, significant effects were still observed at <3 months (headache frequency: SMD = -1.13, 95% CI: -1.90 to -0.35; pain intensity: -0.66 95% CI: -1.02 to -0.30) and at 6-12 months (headache frequency: SMD = -3.95, 95% CI: -7.44 to -0.45; pain intensity: SMD = -2.55 95% CI: -4.73 to -0.36, with no significant improvements at 3-6 months. NIBS also provided short-term benefits in pain duration and analgesic use. Adverse event rates did not differ between groups. Meta-regression linked target and device to short-term efficacy.Conclusion: NIBS is an effective, preventive, and safe treatment for migraine but its long-term efficacy is not evident.","PeriodicalId":16661,"journal":{"name":"Journal of Pain Research","volume":"18 ","pages":"4883-4900"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457775/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JPR.S529622","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Non-invasive brain stimulation (NIBS) has shown promising potential in the treatment of migraine; however, its short- and long-term efficacy remains uncertain. This meta-analysis evaluated the effects of NIBS on multiple migraine-related clinical outcomes in both short- and long-term follow-ups.

Methods: This PRISMA-compliant review (PROSPERO: CRD42024529488) included RCTs on NIBS for migraine. A comprehensive search was conducted in PubMed, Scopus, The Cochrane, EMBASE, Web of Science, CNKI, and VIP up to April 11, 2024. Outcomes consisted of headache frequency, pain intensity, duration, analgesic intake, and adverse effects. Analyses used RevMan 5.3 and STATA 17.0.

Results: Thirteen studies (596 participants) were included. In terms of short-term outcomes, NIBS significantly reduced headache frequency (SMD = -1.47, 95% CI: -2.13 to -0.82) and pain intensity (SMD = -2.09, 95% CI: -3.36 to -0.83). During long-term follow-up, significant effects were still observed at <3 months (headache frequency: SMD = -1.13, 95% CI: -1.90 to -0.35; pain intensity: -0.66 95% CI: -1.02 to -0.30) and at 6-12 months (headache frequency: SMD = -3.95, 95% CI: -7.44 to -0.45; pain intensity: SMD = -2.55 95% CI: -4.73 to -0.36, with no significant improvements at 3-6 months. NIBS also provided short-term benefits in pain duration and analgesic use. Adverse event rates did not differ between groups. Meta-regression linked target and device to short-term efficacy.

Conclusion: NIBS is an effective, preventive, and safe treatment for migraine but its long-term efficacy is not evident.

查看原文本刊更多论文

非侵入性脑刺激治疗偏头痛的短期和长期疗效：一项meta分析。

目的：无创脑刺激（NIBS）在治疗偏头痛方面显示出良好的潜力；然而，其短期和长期疗效仍不确定。本荟萃分析评估了NIBS在短期和长期随访中对多种偏头痛相关临床结果的影响。方法：这项符合prisma标准的综述（PROSPERO: CRD42024529488）纳入了NIBS治疗偏头痛的随机对照试验。全面检索PubMed、Scopus、The Cochrane、EMBASE、Web of Science、CNKI、VIP，截止到2024年4月11日。结果包括头痛频率、疼痛强度、持续时间、止痛药摄入量和不良反应。分析采用RevMan 5.3和STATA 17.0。结果：纳入13项研究（596名受试者）。就短期结果而言，NIBS显著降低了头痛频率（SMD = -1.47, 95% CI: -2.13至-0.82）和疼痛强度（SMD = -2.09, 95% CI: -3.36至-0.83）。结论：NIBS是一种有效的、预防性的、安全的偏头痛治疗方法，但其长期疗效不明显。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pain Research CLINICAL NEUROLOGY-

CiteScore

4.50

自引率

3.70%

发文量

411

审稿时长

16 weeks

期刊介绍： Journal of Pain Research is an international, peer-reviewed, open access journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. Additionally, the journal now welcomes the submission of pain-policy-related editorials and commentaries, particularly in regard to ethical, regulatory, forensic, and other legal issues in pain medicine, and to the education of pain practitioners and researchers.